STABL.ST
Price:
$0.41
Market Cap:
$26.39M
Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
Industry
Biotechnology
IPO Date
2020-03-09
Stock Exchange
STO
Ticker
STABL.ST
According to Stayble Therapeutics AB (publ)’s latest financial reports and current stock price. The company's current ROE is -118.67%. This represents a change of 283.45% compared to the average of -30.95% of the last 4 quarters.
The mean historical ROE of Stayble Therapeutics AB (publ) over the last ten years is 215.58%. The current -118.67% ROE has changed -155.04% with respect to the historical average. Over the past ten years (40 quarters), STABL.ST's ROE was at its highest in in the December 2019 quarter at 1.22%. The ROE was at its lowest in in the December 2024 quarter at -43.84%.
Average
215.58%
Median
-86.25%
Minimum
-180.68%
Maximum
2.69%
Discovering the peaks and valleys of Stayble Therapeutics AB (publ) ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 424.14%
Maximum Annual ROE = 2.69%
Minimum Annual Increase = -3216.65%
Minimum Annual ROE = -180.68%
Year | ROE | Change |
---|---|---|
2024 | -180.68% | 25.65% |
2023 | -143.79% | -9.30% |
2022 | -158.54% | 424.14% |
2021 | -30.25% | -70.70% |
2020 | -103.22% | -103.84% |
2019 | 2.69% | -3216.65% |
2018 | -86.25% | 152.75% |
2017 | -34.12% | 213.51% |
The current ROE of Stayble Therapeutics AB (publ) (STABL.ST) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-161.00%
5-year avg
-123.30%
10-year avg
215.58%
Stayble Therapeutics AB (publ)’s ROE is greater than Imugene Limited (-142.46%), greater than LIDDS AB (publ) (-55.58%), greater than Sprint Bioscience AB (publ) (-184.99%),
Company | ROE | Market cap |
---|---|---|
-142.46% | $2.55B | |
-55.58% | $12.28M | |
-184.99% | $49.42M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Stayble Therapeutics AB (publ) using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Stayble Therapeutics AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Stayble Therapeutics AB (publ)'s ROE?
How is the ROE calculated for Stayble Therapeutics AB (publ) (STABL.ST)?
What is the highest ROE for Stayble Therapeutics AB (publ) (STABL.ST)?
What is the 3-year average ROE for Stayble Therapeutics AB (publ) (STABL.ST)?
What is the 5-year average ROE for Stayble Therapeutics AB (publ) (STABL.ST)?
How does the current ROE for Stayble Therapeutics AB (publ) (STABL.ST) compare to its historical average?